Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2-positive breast cancer. Enhertu has multiple approvals, including tissue-agnostic for high HER2 expression, while datopotamab deruxtecan shows promise in non-squamous NSCLC. Recent findings support ifinatamab deruxtecan's potential to outperform topotecan in second-line treatment, signaling a significant advancement for Daiichi Sankyo's oncology pipeline.
These 2 Stocks Just Hit a New 52-Week High. Time to Bail?
“Let your winners run.” Most investors have heard that sage advice even if it is easier said than done.
Billionaire Investor Warns Of 'Worst Outcome' Economy Possible: Our Approach
A prominent billionaire recently warned of the plausibility of the worst-case scenario for the U.S. economy playing out. We discuss why we think there is a reasonable chance of this happening as well. We share some of our top picks that, we think, will likely weather this scenario quite well.
Agree Realty: The Multiple Expansion Has Not Made The Case Unattractive
Since my earlier piece this June on Agree Realty, the total return performance has landed at close to 25%. This has expanded ADC's multiple quite a lot, and consequently brought down the yield to below 4% level. Theoretically, this renders a strong base of argumentation to consider other alternatives.
If I Could Only Hold 5 REITs Over The Next Decade
I often hold my REITs for just 1-2 years. But there are some exceptions that we expect to hold for the long run. Here 5 REITs that I will hold for the next decade.
3 No-Brainer High-Yield Stocks to Buy With $200 Right Now
Net lease real estate investment trusts require tenants to pay most property-level operating expenses. Although any one location is high-risk for a net lease REIT, those with large portfolios tend to be fairly low-risk.
2 REITs Most Investors Should Own
There is a minority of REITs that check all the boxes. High yield, steady growth, lower risk, and upside potential. I discuss 2 such REITs that most investors should consider.
Places You Routinely Visit Could Provide You With a Pathway Toward a Lifetime of Passive Income
Agree Realty owns retail properties, like grocery stores and home improvement locations. Getty Realty owns gas stations and other auto-related convenience properties.
Rates Down, REITs Up: Two Quality REITs To Own For Long-Term Gains
Agree Realty and CareTrust REIT share prices have rallied since July due to cooling inflation. Additionally, both offer long-term upside due to high-quality business models and strong fundamentals. Agree Realty benefits from investment-grade tenants, a strong balance sheet, and a superior cost of capital, making them less susceptible to economic downturns. CareTrust REIT excels with a low net debt to EBITDA, a strong acquisition pipeline, and a well-covered dividend, positioning them for future growth.
Agree Realty: This REIT Is Almost The Most Expensive In Net Lease
We assigned a Strong Buy rating to ADC due to its superior AFFO growth, lower cost of capital, and trading at a discount. ADC has outperformed the net lease sector, returning 30% since April, driven primarily by multiple expansion from 14.2x to 17.8x forward AFFO. Despite recent gains, ADC is now expensive relative to peers but remains a strong long-term Buy due to its solid business model and CEO alignment.
Understanding Net Lease REITs: Portfolio Quality
Today, we explore portfolio quality, applying the ideas of The Real Estate Chair. The four legs of the real estate chair include tenant credit quality, unit level performance, location, and fungibility of assets. We explore two net lease REITs who apply this concept with varying degrees of success.
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Libtayo, for the treatment of patients with anti-PD-1/anti-PD-L1 relapsed/refractory or unresectable stage III or IV melanoma, met with statistical significance. Positive results obtained from an open-label phase 2 study, using BNT311 + Keytruda for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer; 12-month overall-survival [OS] rate of 69%.
